Sunhee Ro

1.4k total citations
19 papers, 380 citations indexed

About

Sunhee Ro is a scholar working on Molecular Biology, Genetics and Hematology. According to data from OpenAlex, Sunhee Ro has authored 19 papers receiving a total of 380 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Molecular Biology, 8 papers in Genetics and 7 papers in Hematology. Recurrent topics in Sunhee Ro's work include Multiple Myeloma Research and Treatments (6 papers), Protein Degradation and Inhibitors (6 papers) and Chronic Lymphocytic Leukemia Research (5 papers). Sunhee Ro is often cited by papers focused on Multiple Myeloma Research and Treatments (6 papers), Protein Degradation and Inhibitors (6 papers) and Chronic Lymphocytic Leukemia Research (5 papers). Sunhee Ro collaborates with scholars based in United States, France and United Kingdom. Sunhee Ro's co-authors include Heinz Ludwig, Roman Hájek, Richard Bryce, Barbara Klencke, C.G. Morris, Ola Landgren, Kefei Zhou, María‐Victoria Mateos, Bruno Paiva and Hui Yang and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Stroke.

In The Last Decade

Sunhee Ro

18 papers receiving 371 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Sunhee Ro United States	8	229	213	178	54	53	19	380
Thomas G Martin United States	10	318 1.4×	369 1.7×	263 1.5×	36 0.7×	60 1.1×	19	504
David Siegel United States	9	341 1.5×	390 1.8×	265 1.5×	43 0.8×	64 1.2×	23	529
Tomáš Pika Czechia	11	222 1.0×	224 1.1×	129 0.7×	68 1.3×	10 0.2×	67	336
K. Hoekman Netherlands	6	166 0.7×	44 0.2×	128 0.7×	22 0.4×	36 0.7×	11	323
Anri Tienhaara Finland	10	167 0.7×	220 1.0×	161 0.9×	45 0.8×	8 0.2×	20	412
David Kaminetzky United States	8	157 0.7×	58 0.3×	111 0.6×	30 0.6×	10 0.2×	20	303
Enrica Borsi Italy	12	243 1.1×	239 1.1×	157 0.9×	34 0.6×	5 0.1×	26	392
Pierre‐Marie Morice France	7	97 0.4×	35 0.2×	243 1.4×	22 0.4×	81 1.5×	21	382
Anjali Vaze United States	11	112 0.5×	77 0.4×	160 0.9×	26 0.5×	18 0.3×	14	326
Claudia A.M. Stege Netherlands	8	95 0.4×	126 0.6×	110 0.6×	19 0.4×	10 0.2×	15	239

Countries citing papers authored by Sunhee Ro

Since Specialization

Citations

This map shows the geographic impact of Sunhee Ro's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sunhee Ro with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sunhee Ro more than expected).

Fields of papers citing papers by Sunhee Ro

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sunhee Ro. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sunhee Ro. The network helps show where Sunhee Ro may publish in the future.

Co-authorship network of co-authors of Sunhee Ro

This figure shows the co-authorship network connecting the top 25 collaborators of Sunhee Ro. A scholar is included among the top collaborators of Sunhee Ro based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sunhee Ro. Sunhee Ro is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

19 of 19 papers shown

Bewersdorf, Jan Philipp, Xiaoli Mi, Bin Lü, et al.. (2024). Phase Ib Study of PRT543, an Oral Protein Arginine Methyltransferase 5 (PRMT5) Inhibitor, in Patients with Relapsed or Refractory, Splicing Factor-Mutant Myeloid Malignancies. Blood. 144(Supplement 1). 3215–3215. 1 indexed citations

Ro, Sunhee, Qi Jiang, Xiaoyun Li, et al.. (2023). Statistical Considerations on the Use of RWD/RWE for Oncology Drug Approvals: Overview and Lessons Learned. Therapeutic Innovation & Regulatory Science. 57(4). 899–910. 3 indexed citations

Zhang, Weidong, Sunhee Ro, Qing Jiang, et al.. (2022). Statistical and Operational Considerations for 2-Stage Adaptive Designs with Simultaneous Evaluation of Overall and Marker-Selected Populations in Oncology Confirmatory Trials. Therapeutic Innovation & Regulatory Science. 56(4). 552–560. 1 indexed citations

Mesa, Ruben A., Claire Harrison, Jeanne Palmer, et al.. (2022). The Impact of Momelotinib on Patient Reported Quality of Life for Symptomatic and Anemic Patients with Myelofibrosis: Results from the Phase 3 Momentum Study. Blood. 140(Supplement 1). 9677–9680.

Oh, Stephen T., Aaron T. Gerds, Ruben A. Mesa, et al.. (2021). Baseline Serum Ferritin Differentially Predicts W24 Transfusion Independence Response for Momelotinib and Ruxolitinib in Patients with Myelofibrosis. Blood. 138(Supplement 1). 3638–3638. 1 indexed citations

García‐Sánz, Ramón, Meletios Α. Dimopoulos, Marek Trněný, et al.. (2020). Updated results of the ASPEN trial from a cohort of patients with MYD88 wild-type (MYD88^WT) Waldenström macroglobulinemia (WM).. Journal of Clinical Oncology. 38(15_suppl). e20056–e20056. 6 indexed citations

Shadman, Mazyar, Jeff P. Sharman, Moshe Levy, et al.. (2020). Phase 2 Study of Zanubrutinib in Patients with Relapsed/Refractory B-Cell Malignancies Intolerant to Ibrutinib/Acalabrutinib. Blood. 136(Supplement 1). 51–52. 3 indexed citations

Tam, Constantine S., Stephen Opat, Shirley D’Sa, et al.. (2020). ASPEN: Results of a phase III randomized trial of zanubrutinib versus ibrutinib for patients with Waldenström macroglobulinemia (WM).. Journal of Clinical Oncology. 38(15_suppl). 8007–8007. 11 indexed citations

Avet‐Loiseau, Hervé, Heinz Ludwig, Ola Landgren, et al.. (2019). Minimal Residual Disease Status as a Surrogate Endpoint for Progression-free Survival in Newly Diagnosed Multiple Myeloma Studies: A Meta-analysis. Clinical Lymphoma Myeloma & Leukemia. 20(1). e30–e37. 76 indexed citations

10.

Chari, Ajai, A. Keith Stewart, Stuart D. Russell, et al.. (2018). Analysis of carfilzomib cardiovascular safety profile across relapsed and/or refractory multiple myeloma clinical trials. Blood Advances. 2(13). 1633–1644. 50 indexed citations

11.

Cull, Gavin, Stephen Opat, Judith Trotman, et al.. (2017). Safety and Activity of the Highly Specific BTK Inhibitor BGB-3111 in Combination with the PD-1 Inhibitor BGB-A317 in Patients with B-Cell Lymphoid Malignancies. Blood. 130. 4057–4057. 2 indexed citations

12.

Dimopoulos, Meletios Α., A. Keith Stewart, Tamás Masszi, et al.. (2017). Carfilzomib–lenalidomide–dexamethasone vs lenalidomide–dexamethasone in relapsed multiple myeloma by previous treatment. Blood Cancer Journal. 7(4). e554–e554. 44 indexed citations

13.

Squifflet, Pierre, Stefan Michiels, David S. Siegel, et al.. (2015). Relationship Between Carfilzomib Dose and Efficacy Outcomes in Patients With Relapsed and/or Refractory Multiple Myeloma. Clinical Lymphoma Myeloma & Leukemia. 15(11). 680–686. 5 indexed citations

14.

Hájek, Roman, Richard Bryce, Sunhee Ro, Barbara Klencke, & Heinz Ludwig. (2012). Design and rationale of FOCUS (PX-171-011): A randomized, open-label, phase 3 study of carfilzomib versus best supportive care regimen in patients with relapsed and refractory multiple myeloma (R/R MM). BMC Cancer. 12(1). 415–415. 43 indexed citations

15.

Gradishar, William J., Virginia Kaklamani, Tarini Prasad Sahoo, et al.. (2012). A double-blind, randomised, placebo-controlled, phase 2b study evaluating sorafenib in combination with paclitaxel as a first-line therapy in patients with HER2-negative advanced breast cancer. European Journal of Cancer. 49(2). 312–322. 66 indexed citations

16.

Squifflet, Pierre, Stefan Michiels, David S. Siegel, et al.. (2011). Multivariate Modelling Reveals Evidence of a Dose-Response Relationship in Phase 2 Studies of Single-Agent Carfilzomib. Blood. 118(21). 1877–1877. 10 indexed citations

17.

Brophy, Victoria H., Sunhee Ro, Brian Rhees, et al.. (2006). Association of Phosphodiesterase 4D Polymorphisms With Ischemic Stroke in a US Population Stratified by Hypertension Status. Stroke. 37(6). 1385–1390. 49 indexed citations

18.

Liu, Weimin, Sunhee Ro, & Walter Koch. (2005). Making Sense of DNA Microarray Data. Humana Press eBooks. 113. 293–304. 2 indexed citations

19.

Haferlach, Torsten, Alexander Kohlmann, Giuseppe Basso, et al.. (2005). A Multi-Center and Multi-National Program To Assess the Clinical Accuracy of the Molecular Subclassification of Leukemia by Gene Expression Profiling.. Blood. 106(11). 757–757. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact